Are We Getting Closer to Molecular Population Screening for Colorectal Cancer?

Journal of the National Cancer Institute

Volumn 101, Issue 13, 2009, Pages 902-903

  Rennert, Gad ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

VIMENTIN; WNT PROTEIN; MUSCLE PROTEIN; NDRG4 PROTEIN, HUMAN; NERVE PROTEIN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CLINICAL PRACTICE; COLON MUCOSA; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COST; DIAGNOSTIC PROCEDURE; DISEASE COURSE; EDITORIAL; ENDOSCOPY; FALSE POSITIVE RESULT; GENETIC MARKER; HUMAN; IMMUNOLOGICAL TECHNIQUE; MEDICAL TECHNOLOGY; OCCULT BLOOD; OCCULT BLOOD TEST; ONCOGENE C MYB; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN METHYLATION; PUBLIC HEALTH; RADIATION EXPOSURE; RISK; SURVIVAL RATE; SYMPTOM; CHEMISTRY; COLORECTAL TUMOR; DNA METHYLATION; FECES; GENETICS; MASS SCREENING; METHODOLOGY; NOTE; SENSITIVITY AND SPECIFICITY;

COLORECTAL NEOPLASMS; DNA METHYLATION; FECES; HUMANS; MASS SCREENING; MUSCLE PROTEINS; NERVE TISSUE PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 67649657860     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp163     Document Type: Editorial

References (27)

1. Miller AB, eds. Screening for Cancer. Orlando, FL: Academic Press Inc; 1985;9-13,16-18.
2. American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society; 2008.
3. Cancer of the Colon and Rectum (Invasive) Survival Rates, by Race, Sex, Diagnosis Year, Age and Stage at Diagnosis. http://seer.cancer.gov/csr/1975- 2006/browse-csr.php?section=6&page=sect-06-table.11.html. Accessed May 1, 2009.
4. Tanaka T. Colorectal carcinogenesis: review of human and experimental animal studies. J Carcinog. 2009;8:5.
5. Levin B, Lieberman DA, McFarland B, et al. American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society TaskForce; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology [published online ahead of print March 5, 2008]. CA Cancer J Clin. 2008;58(3):130-160.
6. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force [published online ahead of print October 6, 2008]. Ann Intern Med. 2008;149(9):638-658.
7. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328(19):1365-1371. Erratum in: N Engl J Med. 1993;329(9):672.
8. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343(22):1603-1607.
9. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002;50(6):840-844.
10. Jørgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut. 2002;50(1):29-32.
11. Inventory of Colorectal Cancer Screening Activities in ICSN Countries, May 2008. http://appliedresearch.cancer.gov/icsn/colorectal/screening.
12. html. Accessed May 1, 2009.
13. Benson VS, Patnick J, Davies AK, Nadal MR, Smith RA, Atkin WS; on behalf of the International Colorectal Cancer Screening Network. Colorectal cancer screening: a comparison of 35 initiatives in 17 countries. Int J Cancer. 2008;122(6):1357-1367.
14. Rennert G, Rennert HS, Miron E, Peterburg Y. Population colorectal cancer screening with fecal occult blood test. Cancer Epidemiol Biomarkers Prev. 2001;10(11):1165-1168.
15. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population [published online ahead of print March 25, 2008]. Gastroenterology. 2008;135(1):82-90.
16. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics [published online ahead of print September 25, 2007]. J Natl Cancer Inst. 2007;99(19):1462-1470.
17. Pickhardt PJ, Choi JR, Hwang I, et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults [published online ahead of print December 1, 2003]. N Engl J Med. 2003;349(23):2191-2200.
18. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Rabeneck L. Association of colonoscopy and death from colorectal cancer [published online ahead of print December 15, 2008]. Ann Intern Med. 2009;150(1):1-8.
19. Ransohoff DF. How much does colonoscopy reduce colon cancer mortality? [published online ahead of print December 15, 2008]. Ann Intern Med. 2009;150(1):50-52.
20. Kim DH, Pickhardt PJ, Taylor AJ, et al. CT colonography versus colonos- copy for the detection of advanced neoplasia. N Engl J Med. 2007; 357(14):1403-1412.
21. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. N Engl J Med. 2004;351(26):2704-2714.
22. Rennert G, Kislitsin D, Brenner DE, Rennert HS, Lev Z. Detecting K-ras mutations in stool from fecal occult blood test cards in multiphasic screening for colorectal cancer [published online ahead of print March 8, 2007]. Cancer Lett. 2007;253(2):258-264.
23. Zou H, Harrington JJ, Shire AM, et al. Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2686-2696.
24. Chen WD, Han ZJ, Skoletsky J, et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst. 2005;97(15):1124-1132.
25. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149(7):441-450.
26. Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst. 2005;97(15):1107-1109.
27. Melotte V, Lentjes MHFM, van den Bosch SM, et al. N-Myc downstream- regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst. 2009;101(13):916-927.